Global Inflammatory Bowel Disease Treatment Market Research Report 2022 Featuring AbbVie, Biogen, Johnson & Johnson, Amgen, & UCB SA
November 08, 2022 06:13 ET | Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global inflammatory...
evelo-logo.png
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
November 08, 2022 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
logo.png
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials
August 05, 2022 07:30 ET | Arch Biopartners
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with...
evelo-logo.png
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
August 05, 2022 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
evelo-logo.png
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
July 18, 2022 06:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Elixiron Immunotherapeutics Receives Grant From the Alzheimer's Association to Trial Microglia-Targeting Immunotherapy
July 12, 2022 11:01 ET | Elixiron Immunotherapeutics
SAN FRANCISCO, July 12, 2022 (GLOBE NEWSWIRE) -- Elixiron Immunotherapeutics, a clinical stage drug development company announced today that it has received a new grant from the Alzheimer's...
22157.jpg
Global Systemic Lupus Erythematosus (SLE) Market Report 2022-2026: Featuring Pfizer, AstraZeneca, GlaxoSmithKline and Others
June 29, 2022 06:48 ET | Research and Markets
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with...
Does Early Life Inflammation Contribute to the Risk for Developing Psychiatric Conditions?
June 07, 2022 09:50 ET | Brain & Behavior Research Foundation
New York, June 07, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Does Early Life Inflammation Contribute to the Risk for Developing...
evelo-logo.png
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
May 12, 2022 10:47 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, May 12 by Evelo Biosciences, Inc. (Nasdaq: EVLO), please note that in the first sentence...
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
April 29, 2022 18:32 ET | 180 Life Sciences Corp.
The study achieved the primary endpoint of reduction in nodule hardness at 12 months and secondary endpoint of reduction in nodule size at multiple time points including 12 monthsThe treatment arm...